Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Diffusion Pharmaceuticals Inc (DFFN)

Diffusion Pharmaceuticals Inc (DFFN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,989
  • Shares Outstanding, K 97,287
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,800 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade DFFN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9601 +15.61%
on 02/23/21
1.8500 -40.00%
on 02/17/21
+0.0200 (+1.83%)
since 02/01/21
3-Month
0.6640 +67.17%
on 12/16/20
1.8500 -40.00%
on 02/17/21
+0.3600 (+48.00%)
since 12/01/20
52-Week
0.2500 +344.00%
on 03/19/20
1.8500 -40.00%
on 02/17/21
+0.6978 (+169.29%)
since 02/28/20

Most Recent Stories

More News
Diffusion Pharmaceuticals Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed...

DFFN : 1.1100 (-3.48%)
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed...

DFFN : 1.1100 (-3.48%)
Thinking about buying stock in Diffusion Pharmaceuticals, Northern Dynasty Minerals, Zomedica, Sundial Growers, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DFFN, NAK, ZOM, SNDL, and CTXR.

NAK : 0.7900 (-0.10%)
ZOM : 2.06 (+10.16%)
SNDL : 1.3500 (+1.50%)
CTXR : 2.08 (+2.46%)
DFFN : 1.1100 (-3.48%)
Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN.

GTHX : 23.07 (+4.39%)
SBBP : 3.16 (+0.64%)
DFFN : 1.1100 (-3.48%)
PIRS : 2.76 (+1.47%)
SNGX : 1.6300 (-1.21%)
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed...

DFFN : 1.1100 (-3.48%)
Thinking about buying stock in Sundial Growers, Diffusion Pharmaceuticals, Vanda Pharmaceuticals, Aurora Cannabis, or Globalstar?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, DFFN, VNDA, ACB, and GSAT.

ACB.TO : 13.97 (+3.79%)
GSAT : 1.7400 (-1.69%)
SNDL : 1.3500 (+1.50%)
VNDA : 18.74 (+0.48%)
DFFN : 1.1100 (-3.48%)
ACB : 11.04 (+4.94%)
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues...

DFFN : 1.1100 (-3.48%)
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues...

DFFN : 1.1100 (-3.48%)
Thinking about buying stock in Jaguar Health, Diffusion Pharmaceuticals, FuelCell Energy, eMagin Corp, or Fluent Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, DFFN, FCEL, EMAN, and FLNT.

EMAN : 4.52 (+18.02%)
FCEL : 18.69 (+10.33%)
DFFN : 1.1100 (-3.48%)
FLNT : 6.46 (+2.05%)
JAGX : 2.15 (+2.38%)
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) ("Diffusion" or "the Company"), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January...

DFFN : 1.1100 (-3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. The Company is focused on cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant...

See More

Key Turning Points

3rd Resistance Point 1.2667
2nd Resistance Point 1.2233
1st Resistance Point 1.1667
Last Price 1.1100
1st Support Level 1.0667
2nd Support Level 1.0233
3rd Support Level 0.9667

See More

52-Week High 1.8500
Fibonacci 61.8% 1.2388
Last Price 1.1100
Fibonacci 50% 1.0500
Fibonacci 38.2% 0.8612
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar